These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26559642)

  • 21. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
    Montaldi AP; Godoy PR; Sakamoto-Hojo ET
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.
    Ananta JS; Paulmurugan R; Massoud TF
    Neurol Res; 2016 Jan; 38(1):51-9. PubMed ID: 26905383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
    Gong A; Ge N; Yao W; Lu L; Liang H
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
    Zhang C; Yang X; Fu C; Liu X
    Gene; 2018 Sep; 672():172-179. PubMed ID: 29906532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
    Han J; Chen Q
    Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
    Costa PM; Cardoso AL; Nóbrega C; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC
    Hum Mol Genet; 2013 Mar; 22(5):904-18. PubMed ID: 23201752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
    Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
    J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
    Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
    Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
    Khan MB; Ruggieri R; Jamil E; Tran NL; Gonzalez C; Mugridge N; Gao S; MacDiarmid J; Brahmbhatt H; Sarkaria JN; Boockvar J; Symons M
    Mol Med; 2021 Mar; 27(1):28. PubMed ID: 33765907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
    Shang C; Tang W; Pan C; Hu X; Hong Y
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide
    Malhotra M; Sekar TV; Ananta JS; Devulapally R; Afjei R; Babikir HA; Paulmurugan R; Massoud TF
    Oncotarget; 2018 Apr; 9(30):21478-21494. PubMed ID: 29765554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
    Jana A; Narula P; Chugh A; Kulshreshtha R
    Int J Pharm; 2019 Dec; 572():118789. PubMed ID: 31726199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
    Pérès EA; Gérault AN; Valable S; Roussel S; Toutain J; Divoux D; Guillamo JS; Sanson M; Bernaudin M; Petit E
    Oncotarget; 2015 Feb; 6(4):2101-19. PubMed ID: 25544764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
    Jia B; Liu W; Gu J; Wang J; Lv W; Zhang W; Hao Q; Pang Z; Mu N; Zhang W; Guo Q
    Exp Cell Res; 2019 Feb; 375(1):73-81. PubMed ID: 30586549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.
    Tunca B; Tezcan G; Cecener G; Egeli U; Ak S; Malyer H; Tumen G; Bilir A
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1831-44. PubMed ID: 22722712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
    She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Luo Z; Li G; Wu M
    Med Oncol; 2014 Apr; 31(4):892. PubMed ID: 24573637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.
    Ujifuku K; Mitsutake N; Takakura S; Matsuse M; Saenko V; Suzuki K; Hayashi K; Matsuo T; Kamada K; Nagata I; Yamashita S
    Cancer Lett; 2010 Oct; 296(2):241-8. PubMed ID: 20444541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.